Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04416659 · ClinicalTrials.gov registry record
Flow Arrest Safety and Technical Success With Balloon Guide Catheters
A clinical trial, sponsored by Medtronic Neurovascular Clinical Affairs.
- Completed
- Registry status
- 52
- Enrollment target
NCT04416659: Completed study, sponsored by Medtronic Neurovascular Clinical Affairs.
NCT04416659 is a clinical trial that has completed, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04416659 has completed, sponsored by Medtronic Neurovascular Clinical Affairs.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The objective of this post-market registry is to assess technical efficacy and safety associated with the use of the BOSS Balloon Guide Catheter during neuro-vascular procedures while providing temporary arrest of blood flow.
Primary Outcome
Incidence of device-related adverse events
Interventions
- DEVICE Neuro-vascular access
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2021-10-27 |
What the finished NCT04416659 record still lists
NCT04416659 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Neuro-vascular access is the first listed.
NCT04416659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04416659 about?
NCT04416659 is a clinical study titled "Flow Arrest Safety and Technical Success With Balloon Guide Catheters". The objective of this post-market registry is to assess technical efficacy and safety associated with the use of the BOSS Balloon Guide Catheter during neuro-vascular procedures while providing temporary arrest of blood flow.
What is the current status of trial NCT04416659?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2021-01-12. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT04416659?
The interventions under investigation include: Neuro-vascular access (DEVICE).
Who is sponsoring clinical trial NCT04416659?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI